6 known cases. View patent page →
Celgene asserted multiple patents, including the '554 patent, against Natco's lenalidomide ANDA No. 201452. The '554 claims were dismissed without prejudice by stipulation on March 26, 2015; the overall case settled with a consent judgment entered January 4, 2016, and terminated January 5, 2016.
Related patent-infringement action asserting the '517, '230, '740, '569, '357 and '219 patents; consolidated with the 2010 action by order dated November 9, 2012. The narrative could not confirm that the '554 patent was separately asserted in this 2012 action.
D.N.J. case identified through a Docket Alarm patent:(5635517) search as associated with the '517 patent, but the narrative did not retrieve the complaint or judgment to confirm whether the '517 patent was actually asserted or how the case ended.
D.N.J. case identified through a Docket Alarm patent:(5635517) search as associated with the '517 patent, but the narrative did not retrieve the complaint or judgment to confirm whether the '517 patent was actually asserted or how the case ended.
Celgene lenalidomide ANDA suit against Lotus and Alvogen; the '517 patent was expressly named among the patents-in-suit. A consent judgment entered March 29, 2019, included an injunction and dismissal with prejudice, with settlement allowing generic lenalidomide launch after March 2022 under volume limits.
PTAB inter partes review petition challenging U.S. 5,635,517, filed by Coalition for Affordable Drugs VI LLC against Celgene. The Board denied institution on Nov. 16, 2015, and a motion for sanctions was also denied.